MX2020002754A - Inhibidores de cxcr-2 para tratar trastornos. - Google Patents

Inhibidores de cxcr-2 para tratar trastornos.

Info

Publication number: MX2020002754A
Authority: MX; Mexico
Prior art keywords: cxcr; inhibitors; activity; treating disorders; diseases
Prior art date: 2017-09-12

Application number

MX2020002754A

Other languages

English (en)

Spanish (es)

Inventor

Payal Nanavati

Johan Hoegstedt

Jesse Hall

Original Assignee

Ardea Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-12

Filing date

2018-09-12

Publication date

2020-07-20

2017-09-12 Priority claimed from US15/702,693 external-priority patent/US20180221312A1/en

2018-09-12 Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc

2020-07-20 Publication of MX2020002754A publication Critical patent/MX2020002754A/es

Links

239000003112 inhibitor Substances 0.000 title 1
230000000694 effects Effects 0.000 abstract 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 2
102000000589 Interleukin-1 Human genes 0.000 abstract 2
108010002352 Interleukin-1 Proteins 0.000 abstract 2
102000003896 Myeloperoxidases Human genes 0.000 abstract 2
108090000235 Myeloperoxidases Proteins 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000009410 Chemokine receptor Human genes 0.000 abstract 1
108050000299 Chemokine receptor Proteins 0.000 abstract 1
102000019034 Chemokines Human genes 0.000 abstract 1
108010012236 Chemokines Proteins 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
229960001338 colchicine Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
UCCNQCNIPRKLRP-CJNGLKHVSA-N n-[6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide Chemical compound N=1C(SCC=2C=CC(F)=CC=2)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CC(C)C1 UCCNQCNIPRKLRP-CJNGLKHVSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MX2020002754A 2017-09-12 2018-09-12 Inhibidores de cxcr-2 para tratar trastornos. MX2020002754A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15/702,693 US20180221312A1 (en)	2016-03-11	2017-09-12	Cxcr-2 inhibitors for treating disorders
PCT/US2018/050656 WO2019055509A1 (en)	2017-09-12	2018-09-12	INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS

Publications (1)

Publication Number	Publication Date
MX2020002754A true MX2020002754A (es)	2020-07-20

Family

ID=65723077

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MX2020002754A MX2020002754A (es)	2017-09-12	2018-09-12	Inhibidores de cxcr-2 para tratar trastornos.
MX2022014868A MX2022014868A (es)	2017-09-12	2020-03-11	Inhibidores de cxcr-2 para tratar trastornos.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MX2022014868A MX2022014868A (es)	2017-09-12	2020-03-11	Inhibidores de cxcr-2 para tratar trastornos.

Country Status (11)

Country	Link
EP (1)	EP3681861A4 (de)
JP (1)	JP2020533332A (de)
CN (1)	CN111356675A (de)
AR (1)	AR112801A1 (de)
AU (1)	AU2018334152A1 (de)
BR (1)	BR112020004697A2 (de)
CA (1)	CA3075305A1 (de)
CO (1)	CO2020003061A2 (de)
MX (2)	MX2020002754A (de)
TW (1)	TW201919599A (de)
WO (1)	WO2019055509A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113893252A (zh)	2016-03-11	2022-01-07	阿迪亚生命科学公司	用于治疗结晶性关节病症的cxcr-2抑制剂
WO2021061980A1 (en) *	2019-09-25	2021-04-01	The Board Of Trustees Of The Leland Stanford Junior University	Methods for diagnosing and treating uveitis
WO2021089715A1 (en) *	2019-11-06	2021-05-14	Murray And Poole Enterprises, Ltd.	Use of colchicine in the treatment and prevention of lung cancer
EP4058456A1 (de) *	2019-11-13	2022-09-21	RAPT Therapeutics, Inc.	Kristalline formen des c-c-chemokinrezeptor-typ-4-agonisten und deren verwendungen
TW202210068A (zh) *	2020-06-05	2022-03-16	美商雅力思提雅治療公司	用於治療家族性地中海型發熱病的cxcr-2抑制劑
TWI774059B (zh) *	2020-09-14	2022-08-11	國立陽明大學	Ｃｘｃｌ５中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途
TW202227081A (zh) *	2020-09-15	2022-07-16	美商雅力思提雅治療公司	用於治療掌蹠膿疱症之組合物及方法
CN116507346A (zh) *	2020-09-24	2023-07-28	广州辑因医疗科技有限公司	化合物用于提高人造血干细胞移植效率的用途
CN115385865B (zh) *	2022-06-29	2023-06-16	深圳大学	一种具有cxcr2抑制活性的小分子抑制剂及其制备方法与应用
CN117265097B (zh) *	2023-09-20	2026-04-03	复旦大学	一种bach1分子在胰岛素抵抗中的应用
CN117503740A (zh) *	2023-11-09	2024-02-06	复旦大学	一种bach1抑制剂及其应用
EP4686469A1 (de) *	2024-07-31	2026-02-04	Dompé farmaceutici SpA	Cxcl8-inhibitoren zur verwendung bei der behandlung von diabetes-assoziierten erkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2388756C2 (ru) *	2004-01-30	2010-05-10	Шеринг Корпорейшн	Кристаллические полиморфные формы лиганда схс-хемокинового рецептора
US8298533B2 (en) *	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
SI3255043T1 (sl) *	2011-07-12	2021-04-30	Astrazeneca Ab	N-(6-((2R,3S)-3,4-dihidroksibutan-2-iloksi)-2-(4-fluorobenziltio) pirimidin-4-il)-3-metilazetidin-1-sulfonamid, kot modulator kemokinskega receptorja
CN113893252A (zh) *	2016-03-11	2022-01-07	阿迪亚生命科学公司	用于治疗结晶性关节病症的cxcr-2抑制剂

2018
- 2018-09-12 JP JP2020514219A patent/JP2020533332A/ja active Pending
- 2018-09-12 CA CA3075305A patent/CA3075305A1/en active Pending
- 2018-09-12 BR BR112020004697-3A patent/BR112020004697A2/pt not_active IP Right Cessation
- 2018-09-12 WO PCT/US2018/050656 patent/WO2019055509A1/en not_active Ceased
- 2018-09-12 MX MX2020002754A patent/MX2020002754A/es unknown
- 2018-09-12 EP EP18856459.5A patent/EP3681861A4/de not_active Withdrawn
- 2018-09-12 TW TW107132083A patent/TW201919599A/zh unknown
- 2018-09-12 CN CN201880073230.7A patent/CN111356675A/zh active Pending
- 2018-09-12 AR ARP180102592A patent/AR112801A1/es not_active Application Discontinuation
- 2018-09-12 AU AU2018334152A patent/AU2018334152A1/en not_active Abandoned
2020
- 2020-03-11 MX MX2022014868A patent/MX2022014868A/es unknown
- 2020-03-16 CO CONC2020/0003061A patent/CO2020003061A2/es unknown

Also Published As

Publication number	Publication date
CN111356675A (zh)	2020-06-30
TW201919599A (zh)	2019-06-01
WO2019055509A1 (en)	2019-03-21
CO2020003061A2 (es)	2020-06-19
EP3681861A4 (de)	2021-06-09
MX2022014868A (es)	2022-12-15
CA3075305A1 (en)	2019-03-21
EP3681861A1 (de)	2020-07-22
JP2020533332A (ja)	2020-11-19
AU2018334152A1 (en)	2020-04-23
BR112020004697A2 (pt)	2020-10-27
AR112801A1 (es)	2019-12-11

Publication	Publication Date	Title
MX2022014868A (es)	2022-12-15	Inhibidores de cxcr-2 para tratar trastornos.
PH12020552060A1 (en)	2021-07-05	Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
PH12022550359A1 (en)	2023-06-14	Nonpeptide somatostatin type 5 receptor agonists and uses thereof
MX2023000056A (es)	2023-04-12	Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
MX2023009685A (es)	2023-10-30	Inhibidores de tyk2 y sus usos.
MX2023003677A (es)	2023-06-22	Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022016463A (es)	2023-02-01	Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
CO2018010880A2 (es)	2018-10-22	Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales
MX2021015992A (es)	2022-04-06	Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
MX2023009682A (es)	2023-10-30	Inhibidores de tyk2 y sus usos.
MX2023003678A (es)	2023-06-22	Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
NZ757081A (en)	2023-03-31	Somatostatin modulators and uses thereof
AR115583A1 (es)	2021-02-03	Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2023009723A (es)	2023-10-30	Inhibidores de tyk2 y sus usos.
MX2020007586A (es)	2020-09-03	Proceso de fabricacion de moduladores de somatostatina.
GEP20247596B (en)	2024-02-26	Crystalline forms and salt forms of a kinase inhibitor
MX2025008092A (es)	2025-08-01	Inhibidores de kif18a y usos de los mismos
PH12022552447A1 (en)	2024-01-03	Nlrp3 modulators
EA202192047A1 (ru)	2021-12-08	Соединения и их применение
CR20230408A (es)	2024-05-07	Compuestos moduladores de gcn2 y usos de los mismos
PE20210109A1 (es)	2021-01-19	Moduladores de la expresion de irf4
PH12020551179A1 (en)	2021-06-07	Methods for treating mitochondrial disorder
MX2023003675A (es)	2023-06-22	Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021013602A (es)	2022-04-06	Inhibidores de jak.
EP4616848A3 (de)	2025-11-12	Linezolidformulierungen